Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 1.43B -54.0% |
| Revenue (ttm) | n/a |
| Net Income | -349.58M |
| EPS | -4.38 |
| Shares Out | 88.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 392,650 |
| Open | 15.69 |
| Previous Close | 15.55 |
| Day's Range | 15.33 - 15.99 |
| 52-Week Range | 15.34 - 47.65 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 45.22 (+178.96%) |
| Earnings Date | Nov 4, 2026 |
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $45.22, which is an increase of 178.96% from the latest price.
News
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics announces full results from Explore-CKD trial
Mineralys Therapeutics (MLYS) announced that the full results from the Phase 2 Explore-CKD trial of lorundrostat in participants with uncontrolled hypertension, CKD and albuminuria have been published...
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 C...
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics initiated with a Neutral at UBS
UBS initiated coverage of Mineralys Therapeutics (MLYS) with a Neutral rating and $29 price target The company’s lorundrostat, an aldosterone synthase inhibitor for later-line hypertension, is positio...
Mineralys Therapeutics presents new analysis from Launch-HTN trial
Mineralys Therapeutics (MLYS) announced the presentation of a new analysis from its pivotal Phase 3 Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA...
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressur...
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Aldosterone synthase inhibitors are reshaping hypertension treatment, with lorundrostat poised for launch following robust phase III data and strong payer interest. Commercial plans target both specialist and primary care channels, with initial access in fourth-line therapy and expansion expected.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Lorundrostat is advancing toward a December PDUFA date, supported by robust clinical data and a comprehensive commercial build-out targeting third- and fourth-line hypertension. The launch strategy emphasizes parity access, broad prescriber reach, and ongoing R&D, with full funding secured through 2028.
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics reports Q2 EPS ($2.85), consensus (54c)
Research and development expenses for the quarter ended June 30 were $221.4M, compared to $38.3M for the quarter ended June 30, 2025. The increase in R&D expenses was primarily due…
Mineralys Therapeutics price target lowered to $49 from $51 at BofA
BofA lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $49 from $51 and keeps a Buy rating on the shares. The firm’s lower target is driven by lowering…
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw major investments in launch readiness, clinical progress, and capital structure, with lorundrostat positioned for a December PDUFA. Strong cash reserves support operations into 2028, while payer and market feedback remain positive for commercial success.
Mineralys Therapeutics Earnings release: Q2 2026
Mineralys Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Mineralys Therapeutics Quarterly report: Q2 2026
Mineralys Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as C...
Mineralys Therapeutics Slides: Corporate presentation
Mineralys Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Mineralys Therapeutics presents late-breaking data on lorundrostat
Mineralys Therapeutics (MLYS) presented new data on the effect of lorundrostat on heart failure risk biomarkers. This post hoc analysis of circulating proteomic data from participants enrolled in the ...